Develops drugs for cardiovascular and cerebrovascular diseases.
Sep 2025Revenue $37.9M/yrExpenses $50.5M/yr
Fell below break-even Mar 2023Cash runway ≈ 2.5 years from Sep 2025
Figures by year
When will BGM Group be profitable again?
Its expenses passed its revenue in Mar 2023. In the 12 months to Sep 2025, revenue was $37.9M and expenses $50.5M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Sep 2025 | $37.9M | $50.5M | −$12.6M |
| Sep 2024 | $25.1M | $25.7M | −$564K |
| Sep 2023 | $46.5M | $49.1M | −$2.61M |
| Sep 2022 | $64.9M | $62.8M | $2.10M |
| Sep 2021 | $57.1M | $54.7M | $2.39M |
| Sep 2020 | $50.0M | $45.2M | $4.81M |
| Sep 2019 | $46.1M | $39.9M | $6.18M |
| Sep 2018 | $50.4M | $44.4M | $5.97M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.